Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6493096 | 0.94 | NOS2 (0.67) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6490842 | 0.85 | NOS2 (0.47) | NOS2SLC6A4CYP2D6SLC6A2 | |
| SCHEMBL25412202 | 0.80 | NOS2 (0.68) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6553383 | 0.80 | NOS2 (0.39) | NOS2SLC6A4CYP2D6SLC6A2 | |
| SCHEMBL6491319 | 0.80 | NOS2 (0.64) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6497943 | 0.79 | NOS2 (0.47) | NOS2SLC6A4CYP2D6SLC6A2 | |
| SCHEMBL6501101 | 0.79 | NOS2 (0.63) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6499946 | 0.78 | NOS2 (0.61) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| Hydrochloric Acid SCHEMBL6493136 | 0.77 | NOS2 (0.60) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6490554 | 0.76 | NOS2 (1.00) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | claimed |
| EP-1263711-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-12-15 | — | — | EP | claimed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | claimed |
| JP-2003523988-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1263711-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001062704-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | claimed |
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| EP-1263711-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
| EP-1263711-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062704-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | NOS2 3/4885SLC6A4 2468/4885CYP2D6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.